Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of Regen BioPharma Inc from 30 Sep 2017 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
Regen BioPharma Inc quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD history and change rate from 30 Sep 2017 to 31 Mar 2024.
  • Regen BioPharma Inc Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending 31 Mar 2024 was $5,175,963, a 5% decline year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Change (%)

Regen BioPharma Inc Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $5,175,963 -$246,208 -5% 31 Mar 2024 10-Q 24 Apr 2024 2024 Q2
Q4 2023 $5,241,463 -$356,637 -7.3% 31 Dec 2023 10-Q 19 Jan 2024 2024 Q1
Q3 2023 $5,104,000 +$2,932,059 +36% 30 Sep 2023 10-Q 24 Apr 2024 2024 Q2
Q2 2023 $5,028,973 +$3,320,711 +40% 30 Jun 2023 10-Q 25 Jul 2023 2023 Q3
Q1 2023 $4,929,755 +$71,819,675 +94% 31 Mar 2023 10-Q 18 Apr 2023 2023 Q2
Q4 2022 $4,884,826 +$4,871,143 +50% 31 Dec 2022 10-Q 19 Jan 2023 2023 Q1
Q3 2022 $8,036,059 +$5,449,818 +40% 30 Sep 2022 10-K 20 Nov 2023 2023 FY
Q2 2022 $8,349,684 +$4,062,001 +33% 30 Jun 2022 10-Q 22 Jul 2022 2022 Q3
Q1 2022 $76,749,430 -$71,678,717 -1414% 31 Mar 2022 10-Q 21 Apr 2022 2022 Q2
Q4 2021 $9,755,969 -$4,174,713 -75% 31 Dec 2021 10-Q 21 Apr 2022 2022 Q2
Q3 2021 $13,485,877 -$6,150,879 -84% 30 Sep 2021 10-K 15 Nov 2022 2022 FY
Q2 2021 $12,411,685 -$3,852,615 -45% 30 Jun 2021 10-K 22 Dec 2021 2021 FY
Q1 2021 $5,070,713 +$6,698,727 +57% 31 Mar 2021 10-Q 21 Apr 2022 2022 Q2
Q4 2020 $5,581,256 +$2,118,191 +28% 31 Dec 2020 10-Q 21 Apr 2022 2022 Q2
Q3 2020 $7,334,998 +$3,573,797 +33% 30 Sep 2020 10-Q 21 Apr 2022 2022 Q2
Q2 2020 $8,559,070 +$4,227,018 +33% 30 Jun 2020 10-K 22 Dec 2021 2021 FY
Q1 2020 $11,769,440 -$2,954,965 -34% 31 Mar 2020 10-K 22 Dec 2021 2021 FY
Q4 2019 $7,699,447 +$957,385 +11% 31 Dec 2019 10-K 22 Dec 2021 2021 FY
Q3 2019 $10,908,795 -$1,787,124 -20% 30 Sep 2019 10-K 22 Dec 2021 2021 FY
Q2 2019 $12,786,088 -$4,218,890 -49% 30 Jun 2019 10-Q 24 Oct 2019 2019 Q3
Q1 2019 $8,814,475 -$267,764 -3.1% 31 Mar 2019 10-Q 24 Oct 2019 2019 Q3
Q4 2018 $8,656,832 -$856,600 -11% 31 Dec 2018 10-Q 24 Oct 2019 2019 Q3
Q3 2018 $9,121,671 -$3,870,336 -74% 30 Sep 2018 10-K 21 Jun 2021 2019 FY
Q2 2018 $8,567,198 30 Jun 2018 10-Q 24 Oct 2019 2019 Q3
Q1 2018 $8,546,711 31 Mar 2018 10-Q 24 Oct 2019 2019 Q3
Q4 2017 $7,800,232 31 Dec 2017 10-Q 24 Oct 2019 2019 Q3
Q3 2017 $5,251,335 30 Sep 2017 10-Q 24 Oct 2019 2019 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.